ACR-6840, a potential ﬁrst-in-class CDK11 inhibitor, nominated as the next development candidate from company’s AP3-driven cell cycle program, with several promising back-up series also identiﬁed

ACR-6840 - Acrivon Therap

Jan 8, 2026